APASL STC Nagasaki

Poster Free Paper Sessions

17:00~18:30 on April 10 (Mon) 2017

At Room 3 “ASUKA”, 1st Floor

<HBV>

P-001. Transient Elastography is Useful for the Evaluation of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Virus Infection Treated with Entecavir
Masaaki Shimada (Japan)

P-002. Antiplatelet Therapy is Associated with Better Prognosis in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma after Liver Resection
Po-Chun Chen (Taiwan)

P-003. Investigate the Relevant Factors Associated with Low-titer Hepatitis B Surface Antigen Carrier: A Community-based Study
Cheng-Hung Chien (Taiwan)

P-004. Influence of Hepatitis B Virus Genotypes on Innate Immune Response by Impairing Mitochondrial Antiviral Signaling Protein
Kenichi Morikawa (Japan)

P-005. Hepatitis B Virus X Protein Modulates Host Restriction Factor via Interaction with DDB1
Takaaki Izumi (Japan)

P-006. Fusion HBx from HBV Integrant might Alter ER Stress Response and Contribute to Hepatocarcinogenesis
Ryosuke Muroyama (Japan)

P-007. Association of Vitamin D-related Genetic Variations and Treatment Response to Pegylated Interferon in Thai Patients with Chronic Hepatitis B
Umaporn Limothai (Thailand)

P-008. The Value of Using HBsAg and HBcrAg in Combination for the Assessment of HCC Risk
Yuichiro Suzuki (Japan)

P-009. Activated & gamma & delta T Cells Concomitantly Exhibit Cytotoxicity and the Capacity for Viral Clearance in Patients with Acute Hepatitis B
Yuanyuan Li (China)

P-010. MicroRNA 17-92 Induces Methylation of Hepatitis B Virus DNA in Human Hepatoma Cells
In Young Moon (Korea)

P-011. TRAIL Receptor 1 (TRAIL-R1) Polymorphisms are Associated with Risk of Hepatitis B Related Hepatocellular Carcinoma
Apichaya Khlaiphuengsin (Thailand)
P-012. The Characteristics and Outcomes of Patients Dropped out Nucleotide Analogs Therapy  
Shuichi Matsumoto (Japan)

P-013. A Case of Hepatocellular Carcinoma Developed during Administration of Entecavir for De Novo Hepatitis B Reactivation  
Yukiko Okamoto (Japan)

P-014. Association of NTCP Polymorphisms with Clinical outcome of Hepatitis B Infection in a Thai Cohort  
Nongnaput Tuyapala (Thailand)

P-015. Cross Sectional Assessment of Knowledge, Attitude and Practice (KAP) on Hepatitis B and Hepatitis C, Prevalence, and Risk Factors among High Risk Individuals  
Peter Andrew C. Reyes (Philippines)

P-016. Variation in the PreS/S Gene in HBV-associated HCC Patients with the HLA-DPB1 0201 Allele  
Yumi Hakozaki (Japan)

P-017. Hepatitis B Core Related Antigen in Sera is the Surrogate Marker for HBV Covalently Closed Circular DNA Regardless Nucleic Acid Analogues Treatment  
Takeshi Matsui (Japan)

P-018. Usefulness of ALBI Grade in Prediction of Outcomes in Patients with Hepatitis B Related Hepatocellular Carcinoma  
Kazuyuki Mizuno (Japan)

HCV-Post SVR

P-019. Early Recurrence of HCC after Successful Treatment with DCV plus ASV  
Noboru Hirahima (Japan)

P-020. Risk of Hepatocellular Carcinoma after Sustained Virologic Response by Interferon-free Treatment Compared with Interferon-based Treatment for Chronic Hepatitis C  
Naoto Kawabe (Japan)

P-021. Efficacy and HCC Development after DAA Therapy for Patients with Chronic Hepatitis C  
Akitoshi Douhara (Japan)

P-022. Evaluation of Anti Carcinogenic Effect after Antiviral Therapy (PEGRIB and DAA) for Type C Chronic Liver Disease Patients  
Koichi Takaguchi (Japan)

P-023. Recurrence Pattern in Patients who underwent Antiviral Therapy after Curative Treatment of HCV Related Hepatocellular Carcinoma  
Yutaka Yasui (Japan)

P-024. Development of Hepatocellular Carcinoma after Treatment with Direct Acting Antivirals in Hepatitis C Virus-related Chronic Liver Diseases  
Kyo Sasaki (Japan)

P-025. Assessment with Characteristics and Risk of Developing Hepatocellular Carcinoma after Eradication of Hepatitis C Virus by Interferon-free Therapy  
Etsuko Iio (Japan)
P-026. Two Cases of Rapid-growing Hepatocellular Carcinoma after Direct Acting Anti-viral Treatment of Hepatitis C Virus Infection
  Toshihiro Kawaguchi (Japan)

P-027. The Preventive Effect for Recurrence by Interferon-free DAA Treatment in the Patients with HCC Curative Treatment
  Masakuni Tateyama (Japan)

P-028. Development of Hepatocellular Carcinoma in the Patient Occurred Newly just after Sustained Virological Response to Ledipasvir/Sofosbuvir against Chronic Hepatitis C: a Case Report
  Daiki Ozono (Japan)

P-029. The Features of Hepatocellular Carcinoma following Treatment with Direct-acting Antivirals for Hepatitis C
  Seiichi Mawatari (Japan)

P-030. The Incidence of Hepatocellular Carcinoma after Daclatasvir plus Asunaprevir Therapy in HCV-1b Hepatitis who Achieved Sustained Virologic Response
  Mitsuaki Sato (Japan)

P-031. Hepatocellular Carcinoma Occurred after Exclusion of Hepatitis C Virus with Interferon-free Treatment
  Hideo Kunimoto (Japan)

P-032. Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment
  Ming-Lung Yu (Taiwan)

P-033. A Case of Diffuse Hepatocellular Carcinoma Diagnosed after DAA Treatment
  Takeaki Satoh (Japan)

P-034. Characteristics and Prognosis of Patients with Hepatocellular Carcinoma that Developed after Hepatitis-C Virus Eradication
  Tatsuya Minami (Japan)

P-035. Analysis of Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir for Hepatitis C Virus Infection
  Hiroshi Ida (Japan)

<HCV>

P-036. Analysis of the Relationship between Alcohol Drinking and HCV-related Hepatocellular Carcinoma by Estimation of Lifetime Total Alcohol Intake
  Masanori Tokoro (Japan)

P-037. Comparison of the Anti-HCV Effects of IFN-based Therapy and IFN-free Therapy for Patients after Curative HCC Treatment
  Akihiro Tamori (Japan)

P-038. Diversity of the Association of Serum Levels and Genetic Variants of MHC Class I Polypeptide-related Chain A with Liver Fibrosis in Chronic Hepatitis C
  Jee-Fu Huang (Taiwan)
P-039. Effectiveness of Sofosbuvir-based Regimens for Japanese Patients with HCV Genotype 1 or 2 Infection: Real Life Experience from a Multicenter Cohort
Eiichi Ogawa (Japan)

P-040. Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are Associated with Chronic Hepatitis C-Related Hepatocellular Carcinoma
Hoang Hai (Japan)

P-041. Liver Dysfunction Caused by Daclatasvir and Asunaprevir Combination Therapy-its Influence on the SVR Rate and the Association with the Drug-metabolizing Enzyme Polymorphisms
Natsuhiko Kuratomi (Japan)

P-042. Gene Expression Profile on Hepatocellular Carcinoma Cells with Different Intracellular Hepatitis C Viral Load
Chia-Yen Dai (Taiwan)

P-043. Hepatitis C Virus Infection: A Case Series
Angelo Jonathan D. Cruz (Philippines)

P-044. HCV Management in Mongolia
Naranzul Nyamsuren (Mongolia)

P-045. Ledipasvir and Sofosbuvir Treatment Results for Hepatitis C Genotype 1b Patients in Mongolia
Baatarkhuu O (Mongolia)

P-046. The Efficacy of Peginterferon plus Ribavirin in Patients with Genotype 1 Chronic Hepatitis C in Mongolia
Uugantsetseg G (Mongolia)

P-047. Impact of Vitamin D Replacement on Liver Enzymes in Non-Alcoholic Fatty Liver Disease Patients
Suparuedee Boonyagard (Thailand)

P-048. Combination Treatment of Dipeptidyl Peptidase IV Inhibitor (Sitagliptin) and Angiotensin-II Type 1 Receptor Blocker (Losartan) Suppresses Progression in a Nondiabetic Rat Model of Steatohepatitis
Shinya Sato (Japan)

P-049. The Role of PPARβ/δ in CD11b+ Resident Liver Macrophages on Liver Steatosis
Jiapeng K. Chen (Singapore)

P-050. Characteristics of Elderly Patients with Nonalcoholic Fatty Liver Disease
Maki Tobari (Japan)

P-051. The Association between Serum Levels of Sptlc3 and the Clinical Features of Patients with NAFLD
Sho Ijyuin (Japan)
At Room 4 “PEARL”, 12th Floor

<HCC-Basic>

P-052. Anti-tumor Effect of Carnosic Acid on Human Hepatoma Cell Lines
Ting Wang (Japan)

P-053. Antitumoral Effect of SGLT2 Inhibitor against Human Liver Cancer
Kosuke Kaji (Japan)

P-054. Dual Therapy with Acyclic Retinoid and Angiotensin-II Receptor1 Blocker Ameliorates Chemically Induced Hepatocarcinogenesis in Diabetic OLETF Rats
Norihisa Nishimura (Japan)

P-055. Angiotensin II Receptor Blocker Attenuates Human Cholangiocarcinoma through Inhibition of the Hippo-YAP Signaling Pathway
Soichiro Saikawa (Japan)

P-056. Preventive Effects of the Sodium Glucose Cotransporter 2 Inhibitor Tofogliflozin on Liver Tumorigenesis in Obese Mice
Yohei Shirakami (Japan)

P-057. DPP-4 Inhibitor Suppresses the Progression of Hepatocellular Carcinoma through Activation of Chemotaxis of NK Cells in Mice
Sohji Nishina (Japan)

P-058. The Epigenetic Roles of Protein Kinase R in Hepatocellular Carcinoma with Hepatitis C Virus Infection, and Possibility of PKR Inhibitor as a Therapeutic Target
Takao Watanabe (Japan)

P-059. Down-regulated Expression of ANP32B has Anti-apoptotic Function in Hepatocellular Carcinoma
Yoshinori Ohno (Japan)

P-060. The Role of Heme Oxygenase-1 in Liver Cancer Development and Progression
Xiaowen Mao (Hong Kong)

P-061. Systems Approach to Characterize the Metabolism of Liver Cancer Stem Cells Expressing CD133
Seung Kew Yoon (Korea)

P-062. ELK3 Promotes the Migration and Invasion of Liver Cancer Stem Cells by Targeting HIF-1α
Seung Kew Yoon (Korea)

P-063. Histone Deacetylase-targeted Exploration for Expression Inducer of MHC Class I Polypeptide-related Sequence A
Sayaka Ito (Japan)

P-064. Iron Chelator Suppresses Hepatocarcinogenesis through Mitophagy Induction in STAM Mice
Yuichi Hara (Japan)

P-065. Rapid Progression of Hepatocellular Carcinoma in Neuropeptide Y Knockout Mice
Ayaka Kinoshita (Japan)
P-066. Hepatoprotective Effect of Isotoma longiflora (L) Presl. Leaves Extract on Carbon Tetrachloride-induced Hepatotoxicity in Mice
Enikarmila Asni (Indonesia)

P-067. Glycolysis Inhibitors Enhance Inhibition of Hepatoma Cell Growth
Jae Hee Choi (Korea)

P-068. Effect of the Anti-diabetic Drug Metformin in Hepatocellular Carcinoma in Vitro and in Vivo
Asahiro Morishita (Japan)

P-069. Screening, Identification Antivascular Biomarkers of Hepatocellular Carcinoma
Kun Yan (China)

<HCC-Clinical>

P-070. Transarterial Infusion of Epirubicin and Cisplatin Combined with Systemic Infusion of 5-fluorouracil Versus Transcatheter Arterial Chemoembolization Using Doxorubicin for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Sung Won Lee (Korea)

P-071. Does Obesity with Visceral Fat Influence Recurrence and Survival in Patients with Hepatocellular Carcinoma?
Atsushi Hiraoka (Japan)

P-072. Comparison between Percutaneous Radiofrequency Therapy and Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: Early Experience of CyberKnife, SBRT System, in Our Hospital
Yasuhide Motoyoshi (Japan)

P-073. Long-term Survival Result of Patients with Hepatocellular Carcinoma Treated with Trans-arterial Chemoembolization Using Drug-loaded Microspheres
Thai Doan Ky (Vietnam)

P-074. Efficacy of Sorafenib for Hepatocellular Carcinoma and Impact on Prognosis
Taketo Nishina (Japan)

P-075. Treatment of Hepatocellular Carcinoma by Radiofrequency Ablation Using Cool-tip RF Electrode: Prospective Results on 82 Patients
Nguyen Thi Thu Huyen (Vietnam)

P-076. Factors Associated with the Prognosis of Patients with Non-hepatitis B Virus-, Non-hepatitis C Virus-related Hepatocellular Carcinoma
Yu Noda (Japan)

P-077. Non-hypervascular Hepatobiliary Phase Hypointense Nodules on Gd-EOB-DTPA-enhanced MRI as a Risk Factor for Intrahepatic Distant Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation
Masanori Inoue (Japan)

P-078. Analysis of Factors for Respiratory Depression and Severe Body Movement in Radiofrequency Ablation under Deep Sedation
Koki Sato (Japan)
P-079. The Change of Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein (M2BPGi) is A Predictive Marker of the Recurrence of Hepatocellular Carcinoma in Patients after RFA
Masato Nakai (Japan)

P-080. Survival Outcome of Resectable HCC in Young Adult: A Single Center Experience
Sunhawit Junrungsee (Japan)

P-081. Clinicopathological Characteristics of Non-B Non-C Hepatocellular Carcinoma without Past HBV Infection
Takefumi Kimura (Japan)

P-082. Hepatectomy is Beneficial to Intermediate and Advanced Hepatocellular Carcinoma: A Cohort Study in Taiwan
Chi-Ling Chen (Taiwan)

P-083. Sarcopenia as Prognostic Factor in Hepatocellular Carcinoma
Benjamin T Castro Jr (China)

P-084. Three Cases Report of the Sorafenib Treatment for Hepatocellular Carcinoma who are Advanced age, about an Effect and Tolerability
Yasunari Kaneyama (Japan)

P-085. Survival Benefit of Liver Resection for Hepatocellular Carcinoma with Hepatic Vascular Invasion
Yasuhiro Nakayama (Japan)

P-086. Decreased EGFL6 Expression is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Hui Ting Hsu (Taiwan)

P-087. Prognostic Role of Circulating miR-221 in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
Piyawan Chailapakul (Thailand)

P-088. Natural History of Untreated Hepatocellular Carcinoma in Thai Patients: A Single Center Experience
Siwaporn Chainuvati (Thailand)

P-089. Effectiveness of Drug-eluting Bead-transarterial Chemo-embolization in Intermediate Stage of Hepatocellular Carcinoma
Akihiro Deguchi (Japan)

P-090. Pure Laparoscopic Right Hepatectomy for HCC with Umbilical Zigzag Incision
Toshio Shikano (Japan)

P-092. Conversion Therapy with Hepatic Arterial Infusion Chemotherapy for Long-term Prognosis in Patients with Advanced Hepatocellular Carcinoma Involving Vascular Invasion
Hiroaki Nagamatsu (Japan)

P-093. Epidemiology, Clinical Features and Prognosis of Hepatocellular Carcinoma in Mongolia: A Multi-center Study
Baatarkhuu O (Mongolia)
P-094. This paper has been withdrawn

P-095. The Relationship between Malnutrition Universal Screen Tool (MUST) Scores and Liver Function Indexes in Cirrhotic Patients
Ying-Chen Hung (Taiwan)

P-096. Effect of Raloxifene on Rats with Biliary Cirrhosis
Ching-Chih Chang (Taiwan)

P-097. The Mortality of Cirrhotic Patients with Heart Failure
Yen-Chun Chen (Taiwan)

P-098. Food Consumption Behavior in Elderly Cirrhotic Patients
Fang-Yen Kuo (Taiwan)

P-099. A Patient with Liver Cirrhosis Confirmed Reduction in Activity of Lysosomal Acid Lipase (LAL)
Yuki Kugiyama (Japan)

P-100. Efficacy of Tolvaptan for Refractory Ascites in Cirrhotic Patients with Hepatocellular Carcinoma
Motonori Shimizu (Japan)

P-101. Hepatopulmonary Syndrome is Closely Related with Bacterial Translocation in Cirrhosis
Moon Young Kim (Korea)

P-102. Adverse Outcomes after Non-hepatic Surgery in Patients with Liver Cirrhosis: A Nationwide Study
Chien-Chang Liao (Taiwan)

P-103. N Butyl 2 Cyanoacrylate Therapy of Bleeding Gastric Fundal Varices: The Experience of Tertiary Care Hospitals
Farhan Haleem (Pakistan)

P-104. The Role of Partial Splenic Artery Embolization in Cirrhotic Patients with Hypersplenism
Ayman N. Menessy (Egypt)

P-105. Difference of Thrombocytopenia between Alcoholic and Viral LC
Seulki Kim (Korea)

P-106. Fontan-associated Liver Disease: Diagnosis by Elastography and Laparoscopic Liver Biopsy
Yohei Koizumi (Japan)

P-107. The Significance of the Assessment of Liver Stiffness at Medical Health Checkup
Taro Shibuki (Japan)

P-108. Comparative Study of Non-invasive Liver Fibrosis Assessment Methods between Patients with and without Hepatocellular Carcinoma
Akemi Tsutsui (Japan)
P-109. IgG4 Sclerosing Cholangitis and Post Infantile Giant Cell Hepatitis: A Case Report of an Extraordinary Copresentation
   Maha Elabaawy (Egypt)

P-110. Case Report: A Case of Acute Liver Failure in A 52-year Old Female Caused by Autoimmune Hepatitis (AIH) Masquerading as Non-alcoholic Fatty Liver Disease (NAFLD)
   Chuck Eduard B. Galon (Philippines)

P-111. Utilization of Computerized Database System to Facilitate the Efficiency of Case Management for the Chronic Hepatitis B and Hepatitis C Patients in Liver Clinic
   I Ling Liu (Taiwan)

P-112. Epidemiological Study on Age-sex Stratified Prevalence of HBV, HCV and HAV in 1200 Random Samples from General Population and Employees
   Chikako Yamamoto (Japan)

P-113. Fasciola Liver Abscess: An Unrecognized and Fatal but Curable Disease
   Siripa Puasripun (Thailand)

P-114. Mixed Pyogenic and Tuberculous Liver Abscess in 67 Year Old Female
   Francis Rodencio B. Mantilla (Philippines)

P-115. Comparing Response Rate between High Dose and Standard Dose Hepatitis B Vaccination in Cirrhotic Patients
   Petcharee Polmanee (Thailand)

P-116. Post-transplant Diabetes Mellitus after Liver Transplantation: Risk Factors for Persistence
   Yang Won Nah (Korea)

P-117. The Effect of Acute Pancreatitis on the Mortality of Patients with Liver Cirrhosis
   Tsung Hsing Hung (Taiwan)

P-118. The Close Linkage between the Elasticity Modulus Measured by 2D Shear Wave Elastography and the Presence of Hepatocellular Carcinoma in Patients with a SVR to Interferon for CH-C
   Yasuharu Imai (Japan)

P-119. Interventional Oncology (IVO) Suite at Juntendo University, New RFA Treatment Room
   Masashi Takawa (Japan)